In this work, when we integrated IDH results with the intermediate risk cytogenetics, we remarkably found that the OS of the intermediate risk AML group was inferior for mutant IDH patients in comparison with wild IDH patients (median OS 1.8 years vs. 6.4 years, respectively p > 0.05). Here, IDH1 is linked to acute myeloid leukemia.